Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches.
about
Formation of VEGF isoform-specific spatial distributions governing angiogenesis: computational analysisSystems biology of the microvasculatureA systems biology view of blood vessel growth and remodellingControl of cellular motility by neuropilin-mediated physical interactionsA multiscale computational model predicts distribution of anti-angiogenic isoform VEGF165b in peripheral arterial disease in human and mouseComputational and mathematical modeling of angiogenesisVEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model.Multiscale models of angiogenesisSystems biology of vascular endothelial growth factorsA compartment model of VEGF distribution in humans in the presence of soluble VEGF receptor-1 acting as a ligand trapA compartment model of VEGF distribution in blood, healthy and diseased tissues.VEGF signaling mediates bladder neuroplasticity and inflammation in response to BCGPharmacokinetics and pharmacodynamics of VEGF-neutralizing antibodies.Integration of genotypic and phenotypic screening reveals molecular mediators of melanoma-stromal interaction.Computational systems biology approaches to anti-angiogenic cancer therapeutics.Site-Specific Phosphorylation of VEGFR2 Is Mediated by Receptor Trafficking: Insights from a Computational ModelDysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis.Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth.Molecular mechanism matters: Benefits of mechanistic computational models for drug development.Where is VEGF in the body? A meta-analysis of VEGF distribution in cancer.Interleukin-10 deficiency impairs regulatory T cell-derived neuropilin-1 functions and promotes Th1 and Th17 immunity.Expression of VEGF and semaphorin genes define subgroups of triple negative breast cancerVascular endothelial growth factor-A inhibits EphB4 and stimulates delta-like ligand 4 expression in adult endothelial cells.Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: a study based on SWOG protocol S0420Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice.Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.Neuropilin 1: function and therapeutic potential in cancer.Neuropilin-VEGF signaling pathway acts as a key modulator of vascular, lymphatic, and inflammatory cell responses of the bladder to intravesical BCG treatment.Systems biology and physiome projects.Computational models of VEGF-associated angiogenic processes in cancer.Modeling of growth factor-receptor systems from molecular-level protein interaction networks to whole-body compartment models.Multiscale kinetic modeling of liposomal Doxorubicin delivery quantifies the role of tumor and drug-specific parameters in local delivery to tumors.Neuropilin-1 is a glial cell line-derived neurotrophic factor receptor in glioblastoma.Cell-oriented modeling of angiogenesis.
P2860
Q21202775-2455B0EC-599C-4483-B73F-17C59D2FA13FQ26850123-C09F58DF-A144-4B56-A15E-3A4B37A911DAQ27003945-EF80D9BE-8AB2-48C4-A8D7-D727BC959AC4Q27027713-E404869E-6E4C-430D-8764-FD02D08AC5D2Q30275400-EDACA90F-970F-425B-925F-3591B9F1E173Q30431738-EDF95303-8A57-4B46-A6BB-6BBBE0386268Q30432040-C26A6339-F20D-4ACE-A43F-79811A7BCD25Q30432668-E5E79411-053F-479E-9EF3-4020D4DFEFE0Q30438979-5A63D575-9875-46F1-8928-6BAB497F75C9Q30439884-D7FA94BF-8FA5-4FFD-A379-C6C01C86E321Q30441056-7AA3C042-BD81-4F05-AF52-2B30B93839AEQ34068680-05E25A1F-777C-4A3A-8F68-CC3EC4E20653Q34079689-91E42B8E-1EFE-4BFB-A48D-794E581C990BQ34762113-86FD270A-71D3-44E0-A92E-E62F28273343Q35108084-CB3FEA87-F64D-4A9C-AAAC-FA331488E481Q35661415-287DBFE2-2932-44A9-9488-618CAC3CEE43Q35764986-6F3617F5-4E86-4217-90EA-B3F069508B7AQ35826030-845C4D8A-0178-4AAC-ABBE-B7A7291B6987Q36052870-200265C0-B956-4947-88DB-A9568DB91FBFQ36611325-3EFB7F46-CF25-4A5C-833B-14B89DD450C9Q36796532-801FF893-D5AE-4094-BDDC-C1ECCA407103Q36828220-421CB683-7A59-4C85-BAC3-A1275A49FF4DQ36867965-0496D7FA-FF06-4EE5-8628-0AF540DA68DDQ36960552-9AED1EAD-8380-4910-8503-6B207BD8C9D4Q37054876-2BC55B1D-BD9D-4976-B854-011BAE4B6B4CQ37406706-78C52DE6-A082-47AC-ACB6-05364DEAA861Q38165001-C5CEB568-F864-4F9C-A723-E27DF43FCF5AQ39652806-A5609FF1-023B-479D-80D6-822080081E7FQ42049719-95F840A9-004D-407F-A892-E6820574297AQ42098928-5278BDC9-B64C-46F6-9DD9-45253AF6EC3AQ42132001-DB3D7AF7-9E25-470A-9A5F-918CD4DA3A24Q43226325-F5E3F055-67E8-4782-B42C-5F2325420999Q47118020-4DEDB640-62AB-40FB-9B7C-EA6DA947DA67Q51487106-2BD3D63F-F6AD-4BC6-8220-1D8C50163799
P2860
Targeting neuropilin-1 to inhibit VEGF signaling in cancer: Comparison of therapeutic approaches.
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Targeting neuropilin-1 to inhi ...... son of therapeutic approaches.
@ast
Targeting neuropilin-1 to inhi ...... son of therapeutic approaches.
@en
type
label
Targeting neuropilin-1 to inhi ...... son of therapeutic approaches.
@ast
Targeting neuropilin-1 to inhi ...... son of therapeutic approaches.
@en
prefLabel
Targeting neuropilin-1 to inhi ...... son of therapeutic approaches.
@ast
Targeting neuropilin-1 to inhi ...... son of therapeutic approaches.
@en
P2860
P1476
Targeting neuropilin-1 to inhi ...... son of therapeutic approaches.
@en
P2093
Feilim Mac Gabhann
P2860
P356
10.1371/JOURNAL.PCBI.0020180
P577
2006-11-16T00:00:00Z